Key Takeaways
- Strong top-line, injectable investment drags: Revenue grew 21% Y-o-Y in 9M FY25, but the injectable facility carries full depreciation and opex with minimal revenue yet, pressuring near-term margins.
- Trade Generics 3x target hit early: The 3x-in-4-years goal was achieved roughly a year ahead of plan, validating the affordable-medicines distribution strategy.
- Injectable facility is derisked, not derisking: GMP certification is in hand and large-customer audits are scheduled for Q4, but management declined to share any order book, break-even timeline, or capacity utilization targets.
- CDMO lumpiness is structural, not alarming: The 8% Q3 growth reflects B2B production and shipping timing; the quarterly run-rate has held steady at ~₹135-136 crores for several quarters.
- What to watch next quarter: Whether the Q4 large-customer injectable audits convert into disclosed orders, the pace of injectable revenue ramp, and any update on Plant-6 capex and the inorganic pipeline.
Injectable Facility: The Central Bet
- GMP milestone cleared: The injectable facility received GMP certification from Uttarakhand's Food Safety & Drugs Administration in January 2025, confirming compliance with WHO TRS guidelines across all five plants.
- Customer audits imminent: Large customers have scheduled audits of the injectable facility in Q4 FY25, a critical gating step before commercial orders can begin.
- Revenue still negligible: Minimal revenue was recorded in Q3; some will clock in Q4, but the facility must first cross breakeven before contributing to margin through operating leverage.
- Product development on track: Every product incubated in stability has been 100% successful so far, and stability testing commenced in Q3 FY25.
- Export timeline is inherently long: Injectable export products require separate stability batches, dossier filing, and 1.5-2 years of review and approval time plus plant inspection. All steps are ongoing but no specific timeline was provided.
- Margin structure is favorable: Gross margins for injectables will be "very high" compared to oral solids, even for the India business, making the investment a potential margin tailwind once utilization scales.
- Management declined to quantify the ramp: No guidance was given on injectable revenue, capacity utilization, EBITDA break-even timing, or the current operating loss from the facility, citing competitive sensitivity and the cost-plus model.
Hitesh Windlass: "Even in India business, the gross margin for injectable will be very high than gross margin for oral solids. So from a financial perspective, this is all -- it's a win-win."
Trade Generics & Institutional: The Growth Engine
- 21% Y-o-Y growth sustained: The Trade Generics and Institutional verticals drove overall revenue growth of 21% in 9M FY25 and 20% in Q3, despite negative or flattish volume growth and API price reductions that lowered conversion.
- 3x target achieved early: The stated target of tripling the business in four years was reached roughly a year ahead of schedule, reflecting strong execution in market reach expansion.
- Sales force expansion: The sales force has been broadened across key and surrounding territories, enhancing market reach in the trade generics segment.
- Institutional tailwinds are structural: Government focus on Jan Aushadhi Kendras and Ayushman Bharat is expanding the number of consumers covered for medical expenses and pharmaceuticals, creating a long-term demand floor.
- Data understates the opportunity: Published Indian Pharma Market data does not capture a large part of the trade generic segment sold in hinterland markets, potentially creating a perception of a slower market than reality.
- No sub-segment split provided: Management does not disclose a split between Trade Generics and Institutional because products sold in Trade Generics can later be taken into institutional accounts, which require three years of sales history. Institutional business is "clunky" due to rate contracts and irregular bulk supply orders.
Hitesh Windlass: "Our mantra has been Affordable, Accessible and Authentic drugs. So this is where we are. We are in the middle of this opportunity and we have to make the most of it."
CDMO: Steady but Lumpy
- 15% Y-o-Y growth in 9M: The CDMO vertical recorded a 15% Y-o-Y increase over nine months, though Q3 growth slowed to 8% due to B2B production and shipping timing variations.
- Quarterly run-rate is stable: The CDMO business has maintained a quarterly run-rate of approximately ₹135-136 crores for the last three to four quarters, suggesting the underlying demand is intact.
- IP is the margin moat: Management emphasized that owning IP differentiates the CDMO from pure job-work capacity players, and is the reason the business can sustain its current EBITDA margins.
- Schedule M tailwind: The regulatory push for compliance is expected to continue, and companies strong on quality and compliance will "definitely benefit" as smaller competitors face pressure.
Hitesh Windlass: "If you do not have IP, then what are you selling? You're only selling capacity, right? And so when you are only selling capacity and your customer is providing you the material, you're just converting so it's job work; then you cannot have this kind of EBITDA margins."
Exports: Early Innings
- 23% Y-o-Y growth in 9M: Exports reached ₹22.6 crores in the first nine months, with Q3 being the best quarter, though growth remains below desired levels due to the lag between efforts and results.
- ROW and semi-regulated focus: The export strategy targets rest-of-world markets, semi-regulated markets, and South Africa as a regulated market, with partnerships and registrations being added.
- Long incubation period: Dossier filing and approvals require an incubation period of 1 to 1.5 years before business picks up, making exports a slow-build story.
- Injectable exports are further out: Product selection is done and stability batches, dossier compilation, and filing are underway, but the approval cycle adds 1.5-2 years. Management acknowledged exports are "a little bit fag ended" but steps are being taken to expedite where possible.
Hitesh Windlass: "This is the reason why export is a little bit fag ended. And however, we have already we are on the -- we have done our product selection, we are working on taking all the steps that are required to expedite wherever we can."
Costs, Margins & Balance Sheet
- Personnel costs stepped up: Personnel costs rose from ~₹21-22 crores quarterly last year to ~₹32 crores this quarter, driven by business development team expansion across all three verticals, increments, production staff increases, and injectables-related manpower.
- Injectable opex is a near-term drag: The company is carrying the full cost of the injectable facility, including depreciation and operational costs, before significant revenue generation begins, which is compressing margins.
- ROCE target maintained: Management wants to stay around 25% ROCE and above at all times, though the injectable investment cycle will test this in the near term.
- Net cash and working capital undisclosed: Management declined to share net cash as of December or working capital days, stating they are "still within range of what we have been typically."
- Additional capex coming: Further capex is planned for existing oral solid business capacity expansion, with details expected by the end-of-March call.
Capacity Expansion & Inorganic Strategy
- Plant 2 extension fully operational: The extension to the existing plant is now fully online, adding to oral solids capacity.
- Plant-6 brownfield acquisition: Acquired last quarter, this brownfield project will be built out to help reach the ₹1,000 crores revenue target. Layout and machinery identification are in process.
- Existing capacity sufficient for ~₹800 crores: Oral solids and oral liquids capacity can support approximately ₹800 crores in revenue, excluding injectables; Plant-6 build-out takes total capacity to ₹1,000 crores.
- Injectable capacity doubling possible: If orders exceed supply, doubling injectable capacity would be a "very good outcome," pursued in parallel with export efforts, though no timeline was set.
- Inorganic search is deliberate and cautious: Management was close to an acquisition several quarters ago but walked away after diligence found adverse issues. Investment bankers have a clear brief, but the company is being "very choosy" to avoid hidden problems, with no timeline for a deal.
- New dosage forms on the radar: Derma, protein powder, and other dosage forms are being evaluated for inorganic or organic expansion; if no external candidate is found once injectables stabilize, the company will pursue organic entry.
Hitesh Windlass: "For us the most important thing right now is that we have one of the strongest balance sheets, we have a strong growth momentum and we are being very choosy on the inorganic side."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Injectable customer audits | Large customers have scheduled audits of injectable facility | Q4 FY25 |
| Injectable revenue start | Some revenue will clock in Q4, then crossover breakeven | Q4 FY25 and beyond |
| ROCE floor | Stay around 25% and above at all times | Ongoing |
| Plant-6 capex details | Management will comment on layout, machinery, and capex plan | By end-of-March call |
| Revenue capacity target | Reach ₹1,000 crores total capacity with Plant-6 build-out | No date; Plant-6 in planning stage |
| Injectable exports | Stability batches, dossier filing, and approvals in progress | 1.5-2 years from filing for approvals |
Key Metrics
| Metric | Q3 FY25 |
|---|---|
| Revenue | ₹195 cr, +20% YoY |
| 9M FY25 revenue | ₹557.2 cr, +21% YoY |
| EBITDA | ₹24.6 cr, +21% YoY; margin 12.6% |
| 9M FY25 EBITDA | ₹68.6 cr, +22% YoY; margin 12.3% |
| PAT | ₹15.6 cr, +3% YoY |
| 9M FY25 PAT | ₹44.7 cr, +9% YoY |
| CDMO vertical revenue | ₹135.7 cr, +8% YoY |
| Trade Generics & Institutional revenue | ₹49.6 cr, +74% YoY |
| Exports revenue | ₹9.7 cr, +19% YoY |
| 9M FY25 CDMO revenue | ₹407.9 cr, +15% YoY |
| 9M FY25 Trade Generics & Institutional revenue | ₹126.6 cr, +44% YoY |
| 9M FY25 Exports revenue | ₹22.6 cr, +23% YoY |
| Depreciation increase (injectables) | ₹3.6 cr in Q3, almost entirely due to injectable facility |
| ROCE (including injectables) | 27% |
| ROCE (excluding injectables) | 38% |
| Investment in injectables | ~₹75 cr |
| Oral solids and liquids capacity | ~₹800 cr revenue potential, excluding injectables |
| Cash and investments | >₹200 cr in mutual funds, ~₹15-16 cr in fixed deposits |